Fig. 5: SMIM22/GALE promotes glycolysis and proliferation of NSCLC cells.

A, B GEPIA dataset of SMIM22 or GALE expression in NSCLC cases (N = 483) and controls (N = 347). C The linear regression and correlation analyses between SMIM22 and GALE in NSCLC cases. D Immunofluorescence of SMIM22 and GALE in NSCLC cells. E Immunoprecipitation assay suggests an interaction between SMIM22 and GALE. F, G The cell viability of A549 cells after knockdown or over-expressed SMIM22 or GALE. H Glucose uptake of A549 cells after knockdown or over-expressed SMIM22 or GALE. I Lactate production of A549 cells after knockdown or over-expressed SMIM22 or GALE. J–M The ECAR of A549 cells after knockdown or over-expressed SMIM22 or GALE. Error bars represent the means ± SEM of three independent experiments. ∗∗p < 0.01.